These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26055215)

  • 1. 3D-QSAR and docking studies on adenosine A2A receptor antagonists by the CoMFA method.
    Pourbasheer E; Shokouhi Tabar S; Masand VH; Aalizadeh R; Ganjali MR
    SAR QSAR Environ Res; 2015 Jun; 26(6):461-77. PubMed ID: 26055215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling.
    Khanfar MA; Al-Qtaishat S; Habash M; Taha MO
    Chem Biol Interact; 2016 Jul; 254():93-101. PubMed ID: 27216633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists.
    Bacilieri M; Ciancetta A; Paoletta S; Federico S; Cosconati S; Cacciari B; Taliani S; Da Settimo F; Novellino E; Klotz KN; Spalluto G; Moro S
    J Chem Inf Model; 2013 Jul; 53(7):1620-37. PubMed ID: 23705857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA.
    Xu HR; Fu L; Zhan P; Liu XY
    SAR QSAR Environ Res; 2016 Dec; 27(12):999-1014. PubMed ID: 27667445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
    Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
    ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insight into the binding mode and the structural features of the pyrimidine derivatives as human A2A adenosine receptor antagonists.
    Zhang L; Liu T; Wang X; Wang J; Li G; Li Y; Yang L; Wang Y
    Biosystems; 2014 Jan; 115():13-22. PubMed ID: 23665268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
    Zeng H; Zhang H
    J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Aminopyrimidines as dual adenosine A1/A2A antagonists.
    Robinson SJ; Petzer JP; Terre'Blanche G; Petzer A; van der Walt MM; Bergh JJ; Lourens AC
    Eur J Med Chem; 2015 Nov; 104():177-88. PubMed ID: 26462195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
    Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
    J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
    Hao M; Li Y; Wang Y; Yan Y; Zhang S; Li G; Yang L
    J Chem Inf Model; 2011 Oct; 51(10):2560-72. PubMed ID: 21923153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
    Liu G; Wang W; Wan Y; Ju X; Gu S
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists.
    Yang Z; Li X; Ma H; Zheng J; Zhen X; Zhang X
    Bioorg Med Chem Lett; 2014 Jan; 24(1):152-5. PubMed ID: 24332624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A2A receptor.
    Michielan L; Bacilieri M; Schiesaro A; Bolcato C; Pastorin G; Spalluto G; Cacciari B; Klotz KN; Kaseda C; Moro S
    J Chem Inf Model; 2008 Feb; 48(2):350-63. PubMed ID: 18215030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docking-based CoMFA and CoMSIA studies on naphthyl-substituted diarylpyrimidines as NNRTIs.
    Wu HQ; Yao J; He QQ; Chen FE
    SAR QSAR Environ Res; 2014; 25(10):761-75. PubMed ID: 25242254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamate substituted 2-amino-4,6-diphenylpyrimidines as adenosine receptor antagonists.
    Robinson SJ; Petzer JP; Rousseau AL; Terre'Blanche G; Petzer A; Lourens ACU
    Bioorg Med Chem Lett; 2016 Feb; 26(3):734-738. PubMed ID: 26776359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study.
    Moro S; Braiuca P; Deflorian F; Ferrari C; Pastorin G; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
    J Med Chem; 2005 Jan; 48(1):152-62. PubMed ID: 15634009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA.
    Akula N; Lecanu L; Greeson J; Papadopoulos V
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6277-80. PubMed ID: 17049234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of aminoquinazoline derivatives as human A(2A) adenosine receptor antagonists.
    Zhou G; Aslanian R; Gallo G; Khan T; Kuang R; Purakkattle B; De Ruiz M; Stamford A; Ting P; Wu H; Wang H; Xiao D; Yu T; Zhang Y; Mullins D; Hodgson R
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1348-54. PubMed ID: 26781932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Study and Modified Design of Selective Dopamine D3 Receptor Agonists.
    Duan X; Zhang X; Xu B; Wang F; Lei M
    Chem Biol Drug Des; 2016 Jul; 88(1):142-54. PubMed ID: 26851125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.